Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies

Trial Identifier: D8230C00001
Sponsor: AstraZeneca
NCTID:: NCT03263637
Start Date: October 2017
Primary Completion Date: September 2021
Study Completion Date: September 2021
Condition: Leukemia; CLL (Chronic Lymphocytic Leukemia); Myeloma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Dutch Translation
German Translation

Trial Locations

Country Location
Germany Aachen, Germany, 52074
Germany Bonn, Germany, 53127
Germany Göttingen, Germany, 37075
Germany Heidelberg, Germany, 69120
Germany Ulm, Germany, 89081
Netherlands Amsterdam, Netherlands, 1105 AZ
Netherlands Nieuwegein, Netherlands, 3435 CM
United Kingdom Cardiff, United Kingdom, CF14 4XW
United Kingdom Manchester, United Kingdom, M20 4BX
United Kingdom PLYMOUTH, United Kingdom, PL6 8DH
United Kingdom Southampton, United Kingdom, S016 6YD
United Kingdom Sutton, United Kingdom, SM2 5PT